# Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year

> **NCT03700242** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 570 (actual)

## Conditions studied

- Healthy Volunteers (Rabies Immunization)

## Interventions

- **BIOLOGICAL:** HDCV
- **BIOLOGICAL:** HDCV
- **BIOLOGICAL:** PVRV
- **BIOLOGICAL:** PVRV

## Key facts

- **NCT ID:** NCT03700242
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2019-01-19
- **Final completion:** 2020-04-08
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2022-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700242, "Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT03700242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*